DadFinStart your free week
DadFin › Stocks › Healthcare › PRTA

Prothena Corporation plc (PRTA) stock score

Healthcare · Biotechnology · Ireland

$8.84 ▲ +2.67% today

5.6
Dad Score, out of 100
poor

Prothena Corporation plc (PRTA) is a Biotechnology company in the Healthcare sector, listed in Ireland. On DadFin's weekly run it scores 5.6 out of 100 on the Dad Score, a poor reading that places the business ahead of 6% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #930 of 974. Its strongest axis is conviction; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Weak
Growth
Weak
Price action
Average
Risk
Below average
Conviction
Strong
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-5.5×
Dividend yield0.00%
Return on capital-70.2%
Operating margin-1850.2%
Revenue growth (YoY)-92.8%
FCF yield-134.6%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change-15.2%
Market cap$429M
Next earningsNov 5, 2026

What subscribers see on PRTA

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.